ID: ALA2348345

Max Phase: Preclinical

Molecular Formula: C20H23N5O2S

Molecular Weight: 397.50

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  COc1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1

Standard InChI:  InChI=1S/C20H23N5O2S/c1-27-14-5-3-13(4-6-14)24-9-2-10-25(12-11-24)15-7-8-23-20-16(15)17(21)18(28-20)19(22)26/h3-8H,2,9-12,21H2,1H3,(H2,22,26)

Standard InChI Key:  GUHMWSVGSXKDFA-UHFFFAOYSA-N

Associated Targets(Human)

Cyclin-dependent kinase 8/19 99 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 397.50Molecular Weight (Monoisotopic): 397.1572AlogP: 2.70#Rotatable Bonds: 4
Polar Surface Area: 97.71Molecular Species: NEUTRALHBA: 7HBD: 2
#RO5 Violations: 0HBA (Lipinski): 7HBD (Lipinski): 4#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 5.25CX LogP: 2.55CX LogD: 2.55
Aromatic Rings: 3Heavy Atoms: 28QED Weighted: 0.70Np Likeness Score: -1.54

References

1. Saito K, Nakao A, Shinozuka T, Shimada K, Matsui S, Oizumi K, Yano K, Ohata K, Nakai D, Nagai Y, Naito S..  (2013)  Discovery and structure-activity relationship of thienopyridine derivatives as bone anabolic agents.,  21  (7): [PMID:23453217] [10.1016/j.bmc.2013.01.071]
2.  (2020)  3-amino-4-(4-(4 (dimethylcarbamoyl) phenyl)-1,4-diazepan-1-yl) thieno [2,3-b] pyridine-2-carboxamide for use in cancer therapy and formulations comprising the same,